Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupHead and Neck OncologyradiotherapyDiseaseHead and Neck Tumors (Squamous Cell)Nasopharyngeal CarcinomaSubgroupHPV positiveICD10C11.-C11.8C11.9C76.0MeSHHypopharyngeal NeoplasmsLaryngeal NeoplasmsMouth NeoplasmsNasopharyngeal CarcinomaOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckSequenceCETU400/PACL40/CRBP2/Radiation, Head and Neck Tumors, C1 (PID622) -|- CETU250/PACL40/CRBP2/Radiation, Head and Neck Tumors, C2+ (PID621)CETU400/PACL90/CRBP2, Head and Neck Tumors, C1 (PID1242) -|- C2-6 (PID1243) -|- C7-11 (PID1244)CETU400/Radiation, Head and Neck Tumors, C1 (PID1194) -|- CETU250/Radiation, C2+ (PID1195)CISP12/FU600/Radiation, Head and Neck Tumors, C1-2 (PID2059) -|- C3 (PID2060) -|- C4 (PID2062)CISP100/Radiatio, Head and Neck Tumors (PID1334) -|- CISP100/CAPE1000, Nasopharyngeal Ca (PID1784).DOCE60/CISP60/FU600, Nasopharyngeal Ca (PID1373) -|- CISP100/Radiation, Head and Neck Tumors (PID1334)DOCE75/CISP75/FU750, Head and Neck Tumors (PID1102) -|- CRBP1.5/Radiation (PID1282)GEMC1000/CISP80, Nasopharyngeal Ca (PID1325) -|- CISP100/Radiation (PID1334)ChemotherapyChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMitomycinPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMitomycinPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMitomycinPaclitaxelPembrolizumabChemo-substanceCarboplatinCetuximabCisplatinDocetaxelFluorouracilMitomycinPaclitaxelPembrolizumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideNo. Substances12345678Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseInductionneoadjuvantPre-phaseTherapy intentioncurativepalliativeRisksAllergic ReactionAnemia Hb below 8g/dlAstheniaCardiotoxicityConstipationDehydrationDiarrheaDysphagiaEmetogenicity (MASCC/ESMO)EsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHypertensionHyperthyroidismHypomagnesemiaHyponatremiaInfectionsLeukopeniaLymphopeniaMucositisNephrotoxicityNeurotoxicityNeutropeniaOral MucositisOtotoxicityPainPneumoniaPyrexiaRadiation DermatitisRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAdelstein D Bonner JBonner JBrizel DMBudach V Calais GCooper JGhi MHaddad RMaring SMedina JAMehanna HNoronha VPatil VMPosner MSuntharalingam MTao Y Vermorken JWanebo HDiseasefortgeschrittener Kopf-Hals-Tumor, Erstlinie, Stadium III-IV, ECOG 0-1fortgeschrittenes Oropharynxkarzinom, nicht metastasiert, Stadium III-IV, Karnofsky <60Karzinom des Oro- und, Hypopharynx, Larynx, Stadium III und IV, nicht metastasiert, Erstlinie, Karnofsky > 60Kopf-Hals-Tumor,nicht-metastasiert, cisplatinungeeignet, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), adjuvant, ECOG 0-1Kopf-Hals-Tumoren (Plattenepithel-), resektabel, Stadium III-IV, ECOG 0-1Kopf-Hals-Tumoren, cTx cNx cM0, nicht cisplatingeeignet, ECOG 0-2Kopf-Hals-Tumoren, nicht resektabel, UICC Stadium III/IV, ECOG 0-1Kopf-Hals-Tumoren, Plattenepithel-Ca, cT3/cT4, cN0-3, cM0 (bei Zungengrund-Ca max. cT2cN0), 18-75J., ECOG 0-2Kopf-Hals-Tumoren, Stadium III -IV, nicht metastasiert, Erstlinie, ECOG 0-1Kopf-Hals-Tumoren, Stadium III oder IV, ohne Fernmetastasen, Erstlinientherapie, ECOG 0-2Lokal fortgeschrittene Kopf-Hals-Tumoren, Stadium III und IV, adjuvant oder definitive Chemo-Radiotherapie ECOG 0-2lokal fortgeschrittenes, nicht reserzierbares Plattenepithel-Karzinom des Kopf/Halses, Stadium III-IV,M0 Erstlinie, Karnofsky >70Lokal fortgeschrittenes, nicht resezierbares Plattenepithelzellkarzinom des Kopf-Hals-BereichsNeudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1neudiagnostizierter, lokal fortgeschrittener Kopf-Hals-Tumor, Stadium III-IV, Plattenepithel-, ECOG 0-1Nicht resezierbare Kopf-Hals-Tumoren (Plattenepithel-), Stadium III - IV, ECOG 0-1Oropharynxkarzinom (Plattenepithel), HPV-positiv und low-risk (nie Raucher oder weniger als 10 PY), T3N0–T4N0, and T1N1–T4N3, ECOG 0-1OriginCentre Hospitalier Universitaire Tours, France, 94-01 French Head and Neck Oncology and Radiotherapy GroupCleveland Clinic Foundation, ClevelandDana–Farber Cancer Institute, Boston, TAX 324 Study GroupDepartment of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, IndiaDepartment of Medicine, University of Alabama, BirminghamDepartment of Radiation Oncology, University Hospital of Muenster, Muenster, GermanyDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore BDDepartment of Surgery, Landmark Medical Center, Woonsocket, ECOG-ACRIN trial (E2303)Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, USAGORTEC 2015-01 PembroRadHead and Neck Oncology, Dana Farber Cancer Institute, arvard Medical School, Boston, MassachusettsInstitute for Head and Neck Studies and Education (InHANSE), University of Birmingham, UK, De-ESCALaTE HPV trialMedical Oncology Department, Ospedale dell’Angelo, Venezia, the GSTTC Italian Study GroupNew York University Medical Center, New York, Radiation Therapy Oncology Group 9501/IntergroupServicio de Oncologia Radioterapica, Hospital Clinico Universitario, Malaga, SpainTata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, IndiaUniversitair Ziekenhuis Antwerpen, Edegem, BelgiumUniversity Hospitals Charite, Berlin, German Cancer Society 95-06 trialProtocols in Revision 22 protocols foundProtocols under revision.Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1282 V1.0)Carboplatin 70 / Fluorouracil 600 / Radiation, Oropharyngeal Carcinoma (PID1708 V1.0)Cetuximab 250 / Paclitaxel 30 / Carboplatin 1 / Radiation, Head and Neck Tumors, Cycle 7-11 (PID1244 V1.1)Cetuximab 250 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 2+ (PID621 V1.1)Cetuximab 250 / Radiation, Head and Neck Tumors, Cycle 2+ (PID1195 V1.1)Cetuximab 400 / Paclitaxel 40 / Carboplatin 2 / Radiation, Head and Neck Tumors, Cycle 1 (PID622 V1.1)Cetuximab 400 / Radiation, Head and Neck Tumors, Cycle 1 (PID1194 V1.1)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1334 V1.1)Cisplatin 100 / Radiation, Head and Neck Tumors (PID1640 V1.1)Cisplatin 100 / Radiation, Head and Neck Tumors, adjuvant (PID1291 V1.1)Cisplatin 12 / Fluorouracil 600 / Radiation, Head and Neck Tumors, cycle 1-2 (PID2059 V1.0)Cisplatin 16 / fluorouracil 600, Head and Neck Tumors, cycle 3 (PID2060 V1.0)Cisplatin 20 / Fluorouracil 600, Head and Neck Tumors, cycle 4 (PID2062 V1.0)Cisplatin 20 / Fluorouracil 800 / Radiation, Head and Neck Tumors (PID2066 V1.0)Cisplatin 30 / Radiation, Head and Neck Tumors, adjuvant (PID1240 V1.1)Cisplatin 40 / Radiation, Head and Neck Tumors (PID1637 V1.1)Docetaxel 15 / Radiatio, Head and Neck Tumors (PID2259 V1.0)Docetaxel 75 / Cisplatin 75 / Fluorouracil 750, Head and Neck Tumors (PID1102 V1.1)Fluorouracil 600 / Mitomycin 10 / Radiation, Head and Neck Tumors (PID2058 V1.0)Paclitaxel 40 / Carboplatin 1 / Radiation, Head and Neck Tumors (PID2386 V1.0)Paclitaxel 45 / Carboplatin 1.5 / Radiation, Head and Neck Tumors (PID1295 V1.1)Pembrolizumab 200 / Radiation, Head and Neck Tumors (PID2258 V1.0)
